Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06752759 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial
NCT06752759 · ClinicalTrials.gov record · last posted 2026-04-24

Nebulized Ketamine for the Treatment of Major Depressive Disorder

StatusRecruiting
PhasePhase 3
Started2024-10-16
View on ClinicalTrials.gov ↗
from the ClinicalTrials.gov record
This is a double-blind active placebo controlled clinical trial for individuals with moderate to severe depression. The purpose of this study is to assess if nebulized ketamine can reduce depressive symptoms.

Amendment record 2 amendments on the ClinicalTrials.gov record

This ClinicalTrials.gov record has been amended 2 times since 2024-12-23; most recent amendment 2026-04-21. DataLookout shows field-level changes from the day a trial enters its daily monitoring; earlier amendments are counted here from the ClinicalTrials.gov version history. See every version on ClinicalTrials.gov ↗

Trial Details
NCT Number NCT06752759
Lead Sponsor Theresa Jacob, PhD, MPH
Conditions Severe Depression, Moderate Depression, Ketamine, Midazolam, Peripheral Nervous System Agents, Central Nervous System Agents, Neurotransmitter Agents, Physiologic Effects of Drugs +9 more
Enrollment 40 participants
Start Date 2024-10-16
Primary Completion 2027-09-30 (estimated)
Study Completion 2027-09-30 (estimated)
Updated on ClinicalTrials.gov 2026-04-24